M. Lacevic - Concepedia

Concepedia

Author

M. Lacevic

Moffitt Cancer Center

Also Known As

M Lacevic, M. Lacevic, Mensura Lacevic, severe (>800).

17

Publications

1.2K

Citations

8

H-Index

34

Concepts

All Affiliations

Moffitt Cancer Center University of California, San Francisco

ML

About

M. Lacevic is an author at Moffitt Cancer Center specializing in oncology, medicine, and breast cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	98
2	Business	1	1	488
3	Health Sciences	1	1	14
4	Management	1	1	488
5	Public Health	1	1	53

M. Lacevic

×

7

Publications

1.2K

Citations

7

H-Index

	Year	Citations
The uncertainty principle and industry-sponsored research Benjamin Djulbegović, M. Lacevic, Alan Cantor, The Lancet Uncertainty ManagementHigh UncertaintyUncertainty QuantificationManagementExperimental Economics	2000	488
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer Pamela N. Münster, Kenneth T. Thurn, Scott Thomas, British Journal of Cancer	2011	386
Randomized Trial Using Gonadotropin-Releasing Hormone Agonist Triptorelin for the Preservation of Ovarian Function During (Neo)Adjuvant Chemotherapy for Breast Cancer Pamela N. Münster, Amy P. Moore, Roohi Ismail‐Khan, Journal of Clinical Oncology	2012	238
Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy Roohi Ismail‐Khan, S. Minton, Catrin Cox, Journal of Clinical Oncology Reproductive SciencesBreast OncologyReproductive HealthAdjuvant ChemotherapyGynecology	2008	53
Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy Pamela N. Münster, M. Lacevic, Scott Thomas, Journal of Clinical Oncology Breast OncologyHistone Deacetylase InhibitorEstrogen ReceptorGynecologyPharmacotherapy	2009	16
Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy Pamela N. Münster, M. Lacevic, Mark R. Schmitt, Journal of Clinical Oncology Breast OncologyEstrogen ReceptorGynecologyPharmacotherapyHdac Inhibitor	2008	15
Evaluation and appraisal of randomized controlled trials in myeloma Benjamin Djulbegović, Jared Adams, Gary H. Lyman, Annals of Oncology Hematological MalignancyOncologyControlled TrialsHematologyClinical Trials	2001	14

Page 1